Rein Therapeutics Inc.
Organization details
- Legal name
- Rein Therapeutics Inc.
- Former names
- Aileron Therapeutics, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Headquarters city
- Austin
- Headquarters state / province
- Texas
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- RNTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001420565
- EIN
- 13-4196017
Board of directors
-
Alan A. Musso · DirectorSince 2023
-
James Brian Windsor · Director · See RemarksSince 2026
-
Manuel Aivado · DirectorSince 2024
-
Reinhard J. Ambros · DirectorSince 2024
-
Rickenbach Josef H. Von · DirectorSince 2024
-
William Fairey · DirectorSince 2023
Director election results
Annual meeting of July 20, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
65.8%
Board connections
2 of this board's directors also sit on 3 other boards. 2 are in the same sector.
-
Ascendis Pharma A/S Same sectorvia William Fairey
-
Mirum Pharmaceuticals Inc. Same sectorvia William Fairey
- via Alan A. Musso
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $201,804
- 6 purchases by 3 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 27, 2026 | Rickenbach Josef H. Von Director | Open-market purchase | +4,500 | $1.07 | $4,815 |
| May 26, 2026 | Rickenbach Josef H. Von Director | Open-market purchase | +23,190 | $1.06 | $24,581 |
| May 22, 2026 | Rickenbach Josef H. Von Director | Open-market purchase | +15,950 | $1.05 | $16,748 |
| May 21, 2026 | Rickenbach Josef H. Von Director | Open-market purchase | +3,420 | $1.04 | $3,557 |
| Apr 30, 2026 | James Brian Windsor Director, Officer (See Remarks) | Open-market purchase | +25,000 | $1.00 | $25,000 |
| Nov 14, 2025 | Voss Value Master Fund, LP 10% owner | Open-market purchase | +104,183 | $1.22 | $127,103 |
| Oct 28, 2025 | Voss Value-Oriented Special Situations Fund, LP 10% owner | Open-market purchase | +178,392 | $1.39 | $247,965 |
| Oct 27, 2025 | Voss Value-Oriented Special Situations Fund, LP 10% owner | Open-market purchase | +92,642 | $1.37 | $126,920 |
| Oct 27, 2025 | Voss Value-Oriented Special Situations Fund, LP 10% owner | Open-market purchase | +4,840 | $1.37 | $6,631 |
| Oct 24, 2025 | Voss Value-Oriented Special Situations Fund, LP 10% owner | Open-market purchase | +30,176 | $1.39 | $41,945 |
| Dec 5, 2024 | WINDSOR JAMES BRIAN Officer (President and CEO) | Open-market purchase | +239 | $2.24 | $535 |
| Dec 5, 2024 | WINDSOR JAMES BRIAN Officer (President and CEO) | Open-market purchase | +161 | $2.25 | $362 |
| Jun 17, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO 10% owner | Open-market sale | −4,707 | $3.25 | $15,298 |
| Jun 14, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO 10% owner | Open-market sale | −1,900 | $3.30 | $6,270 |
| Jun 12, 2024 | UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO 10% owner | Open-market sale | −9,341 | $3.25 | $30,358 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Rein Therapeutics Inc.
How many directors are on Rein Therapeutics Inc.'s board?
Rein Therapeutics Inc.'s board has 6 directors: Alan A. Musso, James Brian Windsor, Manuel Aivado, Reinhard J. Ambros, Rickenbach Josef H. Von and William Fairey.
Are Rein Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Rein Therapeutics Inc. insiders bought $201,804 of shares in 6 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="rein-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.